Comparative Pharmacology
Head-to-head clinical analysis: NILOTINIB versus VITRAKVI.
Peer-Reviewed Evidence
Head-to-head clinical analysis: NILOTINIB versus VITRAKVI.
NILOTINIB vs VITRAKVI
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Tyrosine kinase inhibitor targeting BCR-ABL, c-KIT, and PDGFR. Binds to inactive conformation of ABL kinase, preventing ATP binding and substrate phosphorylation.
Larotrectinib is a selective inhibitor of the tropomyosin receptor kinases (TRK) A, B, and C. It binds to the ATP-binding site of TRK kinases, preventing their activation and downstream signaling pathways, thereby inhibiting proliferation and inducing apoptosis in tumors with NTRK gene fusions.
300 mg orally twice daily for newly diagnosed chronic phase CML; 400 mg orally twice daily for resistant or intolerant CML. Take on an empty stomach (no food for 2 hours before and 1 hour after).
100 mg orally twice daily
None Documented
None Documented
Clinical Note
moderateNilotinib + Digoxin
"Nilotinib may decrease the cardiotoxic activities of Digoxin."
Clinical Note
moderateNilotinib + Digitoxin
"Nilotinib may decrease the cardiotoxic activities of Digitoxin."
Clinical Note
moderateNilotinib + Deslanoside
"Nilotinib may decrease the cardiotoxic activities of Deslanoside."
Clinical Note
moderateNilotinib + Acetyldigitoxin
"Nilotinib may decrease the cardiotoxic activities of Acetyldigitoxin."
Terminal elimination half-life approximately 17 hours (range 14-20 hours), supporting twice-daily dosing.
Terminal elimination half-life is approximately 16.2 hours (range 12-20 h) in patients; supports twice-daily dosing.
Primarily fecal (93% of absorbed dose) via biliary excretion; renal excretion accounts for <1% of unchanged drug.
Primarily hepatic metabolism, with 39% recovered in feces (36% as unchanged drug) and 18% in urine (0.5% unchanged).
Category D/X
Category C
Kinase Inhibitor
Kinase Inhibitor